View Author
patient treatment survival methylation study cancer glioblastoma radiotherapy trial tumor temozolomide glioma promoter status phase group mgmt promoter methylation prognostic analysis chemotherapy oncol factor adjuvant model eortc grade brain value table month score outcome progression anaplastic hrqol baseline result response fication van den scale methylated agent effect life-year imatinib population sample glioblastoma multiforme research therapy disease toxicity expression signi mgmt methylation status performance status qlq-bn level recurrence classi review probability quality follow-up stupp tumour classi fication university figure probe oncology resection adjuvant temozolomide pattern surgery performance mutation oligodendroglioma prognostic factors
10 Most Recent Publications
|
MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status
(Article)
Bady, P. Sciuscio, D. Mcdonald, D.R. Lacombe, D. Stupp, R. Delorenzi, M. Hegi, M.E. Diserens, A.C. Bloch, J. Bent, M.J. van den Marosi, C. Dietrich, P-Y. Weller, M. Mariani, L. Heppner, F.L. |
2012-10-01
|
|
Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial
(Article)
Hegi, M.E. Janzer, R.C. Hamou, M.F. Bady, P. Weller, M. Bent, M.J. van den Mason, W.P. Mirimanoff, R.O. Stupp, R. Mokhtari, K. Wesseling, P. Lambiv, W.L. Gorlia, T. Kouwenhoven, M.C.M. Hartmann, C. Deimling, A. von Martinet, D. Besuchet Schmutz, N. Diserens, A.C. |
2012-01-16
|
|
An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients
(Article)
Taphoorn, M.J. Claassens, L. Aaronson, N.K. Coens, C. Mauer, M. Osoba, D. Stupp, R. Mirimanoff, R.O. Bent, M.J. van den Bottomley, A. |
2010-04-01
|
|
MGMT promoter methylation in malignant gliomas: Ready for personalized medicine?
(Article)
Weller, M. Stupp, R. Reifenberger, G. Brandes, A. Bent, M.J. van den Wick, W. Hegi, M.E. |
2010-01-01
|
|
EORTC study 26041-22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma
(Article)
Brandes, A. Stupp, R. Hau, P. Lacombe, D. Gorlia, T. Tosoni, A. Mirimanoff, R.O. Kros, J.M. Bent, M.J. van den |
2010-01-01
|
|
Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme
(Article)
Uyl-de Groot, C.A. Stupp, R. Bent, M.J. van den |
2009-06-01
|
|
A novel tool to analyze MRI recurrence patterns in glioblastoma
(Article)
Wick, W. Stupp, R. Rorden, C. Karnath, H.O. Beule, A.C. Bromberg, J.E.C. Ernemann, U. Platten, M. Marosi, C. Mason, W.P. Bent, M.J. van den Weller, M. |
2008-12-01
|
|
Phase II study of imatinib in patients with recurrent gliomas of various histologies: A European organisation for research and treatment of cancer brain tumor group study
(Article)
Raymond, E. Brandes, A. Heinrich, M.C. Gorlia, T. Lacombe, D. Bent, M.J. van den Dittrich, C. Fumoleau, P. Coudert, B. Clement, P.M.J. Frenay, M. Rampling, R. Stupp, R. Kros, J.M. |
2008-10-01
|
|
Frequently asked questions in the medical management of high-grade glioma: A short guide with practical answers
(Article)
Stupp, R. Hottinger, A.F. Bent, M.J. van den Dietrich, P-Y. Brandes, A. |
2008-09-01
|
|
Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: Results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882)
(Article)
Hildebrand, J. Gorlia, T. Kros, J.M. Afra, D. Frenay, M. Omuro, A. Stupp, R. Lacombe, D. Allgeier, A. Bent, M.J. van den |
2008-06-01
|
